Trending

CNS

Nine for 2021: Addressing the pandemic legacy

Nine for 2021: Addressing the pandemic legacy

In this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact

X

Nine for 2021: Addressing the pandemic legacy

https://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with

X

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

https://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/

Finding the big picture for Alzheimer’s

Finding the big picture for Alzheimer’s

The $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’

X

Finding the big picture for Alzheimer’s

https://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/

A bright future for CNS and Alzheimer’s?

A bright future for CNS and Alzheimer’s?

Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare

X

A bright future for CNS and Alzheimer’s?

https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/

Regeneron and Alnylam announce $1bn collaboration

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and

X

Regeneron and Alnylam announce $1bn collaboration

https://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of

X

Pfizer’s CNS exit takes the form of a biotech spinout

https://pharmaphorum.com/news/pfizers-cns-exit-takes-the-form-of-a-biotech-spinout/

Tysabri failure in stroke a setback for Biogen

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.

X

Tysabri failure in stroke a setback for Biogen

https://pharmaphorum.com/news/tysabri-failure-stroke-setback-biogen/

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.

X

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

https://pharmaphorum.com/views-and-analysis/janssen-mental-health-psychiatry/

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

David Epstein, who left his job as head of Novartis’ pharma division in May, has joined Remedy Pharmaceuticals

X

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

https://pharmaphorum.com/news/ex-novartis-chief-epstein-joins-remedy-pharmaceuticals/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com